First patients treated in Phase I/II trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer
NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumours
The first patients have treated in NOXXON Pharma's Phase I/II clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany. The goal of the trial is to evaluate safety and the effects of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumours in addition to safety and efficacy of NOX-A12 in combination with Keytruda (pembrolizumab), a programmed death receptor-1 (PD-1) immune checkpoint-inhibiting antibody marketed by Merck & Co./MSD.
NOXXON and Merck & Co./MSD collaborated closely in the two-arm clinical trial design that is composed of two parts: patients will receive NOX-A12 monotherapy for 2 weeks, followed by combination therapy of NOX-A12 plus Keytruda for up to 2 years. The open-label trial is designed to include 20 patients, 10 patients for each metastatic pancreas and colorectal cancer.
Two patients have now completed part 1 of the trial in which they received NOX-A12 monotherapy for 2 weeks. Data from this stage will be used to analyse safety and, through tumour biopsies taken before and after NOX-A12 treatment, the ability of NOX-A12 to modulate the tumour microenvironment including the number of T-cells present in the tumours. Part 1 could, as such, provide clinical data to support the broad potential applicability for combinations of NOX-A12 not only with checkpoint inhibitors but also other T-cell based therapeutics such as CAR-T approaches. If successful, this avenue of therapeutic intervention could potentially become game-changing for a wide range of cancers. Both patients that completed part 1 have now progressed into part 2, receiving NOX-A-12 in combination with Keytruda. Top-line data for all 20 patients from part 1 is targeted to be available in Q2 2018, and initial response-rate data in Q4 2018.
“We believe that our lead product NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumours. We would like to thank the team at the National Center for Tumor Diseases in Heidelberg (Germany) for the excellent start to this trial, which will provide us with the first human data to test this hypothesis,” said Jarl Ulf Jungnelius, Chief Medical Officer of NOXXON Pharma. “Our interactions with the Merck team and the strong preclinical data we have generated underscore NOX-A12’s potential as a future component of innovative treatment for patients suffering from colorectal and pancreatic cancers.”
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance